Medicines and machines built from folded DNA

How far are DNA origami and DNA nanostructures from use in medicine and devices?

DNA origami has moved from folding shapes in test tubes to testing in animals. A 2018 Nature Biotechnology paper reported a DNA nanorobot that carried a blood-clotting enzyme to tumour blood vessels in mice, and the authors reported it as safe in mice and miniature pigs. A ClinicalTrials.gov search for 'DNA origami' on 21 October 2026 returned no registered studies. The sources reviewed do not give a cost per gram for clinical-grade material or measured stability in blood.

AI illustration · Illustrative scene, not a photograph of the specific device or experiment.
WHERE WE AREEngineering prototypes

Getting closer. Prototypes exist, but not in real-world use.

Folded DNA nanorobots have been shown to carry a payload to tumours in mice, as reported in a peer-reviewed paper, and the method has been produced at litre scale in a bioreactor. No human study has been found, and the sources reviewed do not give manufacturing cost per gram or measured stability in blood. That places the field between a working prototype and a pilot, so the stage is engineering prototype.

The tech tree

Everything recorded on Vrulum that this future needs, oldest foundations at the top and the goal at the bottom. Lines show what each step requires.

What it takes: Medicines and machines built from folded DNA Unlocked Being researched Locked
  1. 2006DNA nanotechnology and DNA origamiResearch and prototypes Being researched.
  1. 2006Folding DNA into nanoscale shapesDone Unlocked.
  2. 2017Producing DNA origami strands at larger scaleDone Unlocked.
  3. 2018Animal safety and clearanceDone Unlocked.
  4. 2018Animal studies in other disease modelsIn progress Being researched.
  5. 2018Targeted delivery in tumour-bearing miceDone Unlocked.
  6. 2026Human clinical trialNot started Locked.
  7. Date not recordedStability in blood and clinical-grade manufacturing costNot started Locked.
  1. GoalMedicines and machines built from folded DNAGoalRequires: DNA nanotechnology and DNA origami, Folding DNA into nanoscale shapes, Producing DNA origami strands at larger scale, Targeted delivery in tumour-bearing mice, Animal safety and clearance, Animal studies in other disease models, Human clinical trial, Stability in blood and clinical-grade manufacturing cost. Locked.

The road so far

4 of 7 steps done, 1 in progress.

  1. Done · Mar 2006Folding DNA into nanoscale shapes

    Rothemund's 2006 method folded a single-stranded DNA scaffold of about 7 kilobases into nanoscale shapes, held in place by more than 200 short staple strands. The reported structures are roughly 100 nm in diameter, with a spatial resolution of 6 nm. [1]

  2. Done · 2017Producing DNA origami strands at larger scale

    Praetorius and colleagues used bacteriophage-derived DNA to produce the single-stranded precursor DNA for scaffold and staple strands. They made the staple strands in shaker-flask cultures and produced a DNA origami nanorod at litre scale in a stirred-tank bioreactor. The abstract describes scaffold production as scalable and says staple strands are costly to make. No cost per gram is given in the sources opened. [2]

  3. Done · Mar 2018Targeted delivery in tumour-bearing mice

    Li and colleagues built a DNA origami nanorobot that carries thrombin inside a cavity and is opened by a nucleolin-binding aptamer. After intravenous injection in tumour-bearing mice, the robots delivered thrombin to tumour blood vessels, causing clots, tumour necrosis and slower tumour growth. The abstract does not give dosing, sample sizes or methods, so these details could not be checked. [3][4]

  4. Done · Feb 2018Animal safety and clearance

    The authors report that the nanorobot appeared safe and immunologically inert in mice and Bama miniature pigs. The press summary says most nanorobots were cleared or degraded within 24 hours, and reports no detectable changes in normal blood clotting or cell morphology. The press summary does not set out the study's limitations, so these claims are not checked against full data. [3][4]

  5. In progress · Feb 2018Animal studies in other disease models

    The 2018 study used breast, melanoma, ovarian and lung cancer models in mice. In the melanoma model, 3 of 8 mice showed complete tumour regression, according to a press summary of the study. A separate lung model showed shrinkage after two weeks of treatment. These results come from one collaboration and have not been repeated by independent teams in the sources reviewed. [4]

  6. Not started · 21 Oct 2026Human clinical trial

    A ClinicalTrials.gov API search for 'DNA origami' on 21 October 2026 returned no studies. The Harvard Gazette's 2012 report describes a DNA robot tested on leukaemia and lymphoma cells and does not mention animal or patient testing. [6][5]

  7. Not startedStability in blood and clinical-grade manufacturing cost

    The sources reviewed do not give measured stability figures for DNA origami in blood, or a cost per gram for clinical-grade material. The 2018 animal study reports most nanorobots clearing within 24 hours, which shows short persistence in the body rather than long-term stability. [2][4]

Why it matters

If DNA structures can be made cheaply and stay intact in the body, they could become programmable tools for targeted drug delivery and molecular diagnostics. So far the evidence is from cell cultures and mice, and much of what is known about the animal work comes from abstracts and press summaries rather than full methods. Independent results and a first human study would show how much of that potential holds.

What stands in the way

  • No registered human study of DNA origami was found in a ClinicalTrials.gov search on 21 October 2026. That search used one term only, so studies registered under other names may exist.
  • The animal evidence so far comes from one collaboration, using a few mouse tumour models and a pig safety study. Independent repeats were not found in the sources reviewed.
  • Most of the nanorobots in the 2018 study cleared or degraded within 24 hours, so a longer-lasting design or a different dosing approach would need to be shown.
  • The sources reviewed do not give a cost per gram for clinical-grade DNA origami, or the cost of making the short staple strands at that scale.
  • The sources reviewed do not give measured stability figures for DNA structures in blood or tissue, which is a known design concern for molecular devices.

Signals to watch

  • A first-in-human study of a DNA origami or DNA nanostructure drug carrier registered on ClinicalTrials.gov.
  • Independent groups repeating the 2018 tumour results in animals, with full methods, dosing and sample sizes published.
  • A peer-reviewed cost per gram for clinical-grade DNA origami, with a stated production method and scale.
  • Published measurements of how long DNA origami structures stay intact in blood or serum in animals.
  • Pre-clinical safety studies in a second large animal species with reported immune responses.

Sources

  1. peer reviewed paper
    Folding DNA to create nanoscale shapes and patterns
    Paul W. K. Rothemund. Nature, Mar 2006.
  2. peer reviewed paper
    Biotechnological mass production of DNA origami
    Florian M. Praetorius, Benjamin Kick, Karl L. Behler et al.. Nature, 2017.
  3. peer reviewed paper
    A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
    Suping Li, Qiao Jiang, Shaoli Liu et al.. Nature Biotechnology, Mar 2018.
  4. news
    Cancer-fighting nanorobots programmed to seek and destroy tumors
    ScienceDaily (repost of an Arizona State University press release), 12 Feb 2018.
  5. university press release
    Sending DNA robot to do the job
    Twig Mowatt. Harvard Gazette (Wyss Institute communications), 16 Feb 2012.
  6. dataset
    ClinicalTrials.gov API query: 'DNA origami' (pageSize 20)
    ClinicalTrials.gov (US National Library of Medicine), 21 Oct 2026.

Last reviewed 21 Oct 2026.